Nouvelles Eulerpool Aquestive Therapeutics

Eulerpool-AFX Aquestive Therapeutics

Aquestive Therapeutics Actualités des actions

Aquestive Therapeutics est surveillé par de nombreux journalistes et investisseurs du monde entier. Nous regroupons ici les dernières actualités Aquestive Therapeutics.

• 25 octobre ·

  Yahoo
  Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study
• 25 octobre ·

  Yahoo
  Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting
• 25 octobre ·

  TipRanks
  Aquestive Therapeutics’ Favorable OAS Study Boosts Anaphylm’s Prospects with Raised Price Target and Buy Rating
• 25 octobre ·

  TipRanks
  Aquestive to present subsequent analysis of data from Anaphylm study
• 25 octobre ·

  TipRanks
  Piper Sandler Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)
• 25 octobre ·

  TipRanks
  Strong Buy Rating for Aquestive Therapeutics’ Anaphylm™ Driven by Promising Study Results and Market Potential
• 24 octobre ·

  Yahoo
  Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
• 24 octobre ·

  TipRanks
  Aquestive Therapeutics’ Anaphylm: Rapid and Reliable Allergy Treatment Gains ‘Buy’ Rating
• 24 octobre ·

  TipRanks
  Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
• 24 octobre ·

  TipRanks
  Aquestive announces primary, secondary endpoints met in OAS challenge study